- Home
- BLX vs CGON Comparison
BLX vs CGON Comparison
Compare BLX & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLX
- CGON
- Stock Information
- Founded
- BLX 1977
- CGON 2010
- Country
- BLX Panama
- CGON United States
- Employees
- BLX N/A
- CGON N/A
- Industry
- BLX Commercial Banks
- CGON
- Sector
- BLX Finance
- CGON
- Exchange
- BLX Nasdaq
- CGON NYSE
- Market Cap
- BLX 1.4B
- CGON 1.3B
- IPO Year
- BLX N/A
- CGON 2024
- Fundamental
- Price
- BLX $41.17
- CGON $26.91
- Analyst Decision
- BLX
- CGON Strong Buy
- Analyst Count
- BLX 0
- CGON 10
- Target Price
- BLX N/A
- CGON $64.00
- AVG Volume (30 Days)
- BLX 103.5K
- CGON 960.5K
- Earning Date
- BLX 07-22-2025
- CGON 05-13-2025
- Dividend Yield
- BLX 6.10%
- CGON N/A
- EPS Growth
- BLX 13.55
- CGON N/A
- EPS
- BLX 5.60
- CGON N/A
- Revenue
- BLX $289,499,000.00
- CGON $662,000.00
- Revenue This Year
- BLX $13.23
- CGON N/A
- Revenue Next Year
- BLX $7.79
- CGON $12,387.03
- P/E Ratio
- BLX $7.30
- CGON N/A
- Revenue Growth
- BLX 13.37
- CGON 224.51
- 52 Week Low
- BLX $27.37
- CGON $14.80
- 52 Week High
- BLX $42.88
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- BLX 57.69
- CGON 58.13
- Support Level
- BLX $40.45
- CGON $26.25
- Resistance Level
- BLX $41.90
- CGON $27.15
- Average True Range (ATR)
- BLX 0.70
- CGON 1.28
- MACD
- BLX -0.08
- CGON 0.06
- Stochastic Oscillator
- BLX 71.48
- CGON 70.13
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.